Literature DB >> 16086592

Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers.

Aarti Bhatia1, Hans-Jochen Schäfer, Christine A Hrycyna.   

Abstract

Human ABCG2, a member of the ATP binding cassette (ABC) transporter superfamily, is overexpressed in numerous multidrug-resistant cells in culture. Localized to the plasma membrane, ABCG2 contains six transmembrane segments and one nucleotide binding domain (NBD) and is thought to function as a dimer or higher order oligomer. Chimeric fusion proteins containing two ABCG2 proteins joined either with or without a flexible linker peptide were expressed at the plasma membrane and maintained drug transport activity. Expression of an ABCG2 variant mutated in a conserved residue in the Walker B motif of the NBD (D210N) resulted in a non-functional protein expressed at the cell surface. Expression of an ABCG2 chimeric dimer containing the D210N mutation in the first ABCG2 resulted in a dominant-negative phenotype, as the protein was expressed at the surface but was not functional. Using a bifunctional photoaffinity nucleotide analogue and a non-membrane-permeable cysteine-specific chemical cross-linking agent, a dimer is the predominant form of oligomerized ABCG2 under our assay conditions. Furthermore, these experiments demonstrated that the dimer interface includes, but may not be limited to, interactions between residues in each monomeric NBD and separate disulfide interactions between the cysteines in the third extracellular loop of each monomer. By changing all three extracellular cysteines to alanine, we showed that although extracellular disulfide bonds may exist between monomers, they are not essential for ABCG2 localization, transport activity, or prazosin-stimulated ATPase activity. Together, these data suggest that ABCG2 functions as a dimer, but do not exclude functional higher order oligomers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086592     DOI: 10.1021/bi0503807

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

1.  Recombinant synthesis of human ABCG2 expressed in the yeast Saccharomyces cerevisiae: an experimental methodological study.

Authors:  Anna Jacobs; Dana Emmert; Svenja Wieschrath; Christine A Hrycyna; Michael Wiese
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

2.  The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.

Authors:  Karin F K Ejendal; Ndeye Khady Diop; Linda C Schweiger; Christine A Hrycyna
Journal:  Protein Sci       Date:  2006-07       Impact factor: 6.725

3.  Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.

Authors:  Zhanglin Ni; Michelle E Mark; Xiaokun Cai; Qingcheng Mao
Journal:  Int J Biochem Mol Biol       Date:  2010

Review 4.  Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions.

Authors:  Rebecca R Crawford; Praveen K Potukuchi; Erin G Schuetz; John D Schuetz
Journal:  Drug Metab Dispos       Date:  2018-03-07       Impact factor: 3.922

Review 5.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

Review 6.  The ABCG family of membrane-associated transporters: you don't have to be big to be mighty.

Authors:  Ian D Kerr; Ameena J Haider; Ingrid C Gelissen
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 7.  Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.

Authors:  Peyman Ranji; Tayyebali Salmani Kesejini; Sara Saeedikhoo; Ali Mohammad Alizadeh
Journal:  Tumour Biol       Date:  2016-08-26

8.  Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

Authors:  Nagdeep Giri; Sagar Agarwal; Naveed Shaik; Guoyu Pan; Ying Chen; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

9.  Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport.

Authors:  Yue-xian Hou; Chang-Zhong Li; Kanagaraj Palaniyandi; Paul M Magtibay; Laszlo Homolya; Balazs Sarkadi; Xiu-bao Chang
Journal:  Biochemistry       Date:  2009-09-29       Impact factor: 3.162

10.  Arginine 383 is a crucial residue in ABCG2 biogenesis.

Authors:  Orsolya Polgar; Lilangi S Ediriwickrema; Robert W Robey; Ajay Sharma; Ramanujan S Hegde; Yongfu Li; Di Xia; Yvona Ward; Michael Dean; Csilla Ozvegy-Laczka; Balazs Sarkadi; Susan E Bates
Journal:  Biochim Biophys Acta       Date:  2009-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.